AMLX
Amylyx Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+15/100
Last price
27.68
▼ 0.36 (1.28%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
27.90
Prev close
28.04
Day high
28.46
Day low
27.21
Volume
746.45K
Market cap
$3.47B
P/E (TTM)
—
52W range
10.83 – 41.14
Day trading desk
Gap from prior close
-0.50%
Prior close 28.04
VWAP
28.11
-1.54% from price
Relative volume
0.32×
Quiet session
Session range
4.59%
27.21 – 28.46
Position in range
38%
Mid range
ATR (14D)
1.36
4.90% of price
Prior day high
28.50
PDH
Prior day low
27.00
PDL
Bid / ask spread
—
Quote not published
Session volume
747.04K
Avg 2.31M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.88%
-6.8%
1M
-18.30%
-19.8%
3M
+50.60%
+47.2%
6M
+63.59%
+48.6%
YTD
+129.14%
+115.1%
1Y
+118.12%
+102.4%
3Y
+52.76%
-29.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AMLX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+119.47K
Net buying
Buy transactions
7
240.78K shares
Sell transactions
6
121.30K shares
Net transactions
+13
Buys less sells
Sell : buy shares
0.5 : 1
Mixed
Insider-held shares
8.00M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 10, 26 | BEDROSIAN CAMILLE L Officer |
SELL | 10.03K | $324.87K | Direct |
| Sep 10, 26 | FRATES JAMES MATTHEW Chief Financial Officer |
SELL | 10.81K | $349.82K | Direct |
| Sep 10, 26 | COHEN JOSHUA BARRY Chief Executive Officer |
SELL | 30.46K | $980.50K | Direct |
| Sep 10, 26 | KLEE JUSTIN B Chief Executive Officer |
SELL | 30.46K | $980.26K | Direct |
| Sep 10, 26 | MAZZARIELLO GINA Officer |
SELL | 9.54K | $309.51K | Direct |
| Aug 31, 26 | FIRESTONE KAREN M. Director |
CONVERSION | 50.00K | $170.25K | Direct |
| Aug 18, 26 | BEDROSIAN CAMILLE L Officer |
STOCK | 22.81K | $0 | Direct |
| Aug 18, 26 | FRATES JAMES MATTHEW Chief Financial Officer |
STOCK | 22.81K | $0 | Direct |
| Aug 18, 26 | COHEN JOSHUA BARRY Chief Executive Officer |
STOCK | 60.04K | $0 | Direct |
| Aug 18, 26 | KLEE JUSTIN B Chief Executive Officer |
STOCK | 60.04K | $0 | Direct |
| Aug 18, 26 | MAZZARIELLO GINA Officer |
STOCK | 21.28K | $0 | Direct |
| Jul 10, 26 | MAZZARIELLO GINA Officer |
SELL | 30.00K | $538.87K | Direct |
| May 21, 26 | FIRESTONE KAREN M. Director |
BUY | 3.80K | $51.34K | Direct |
| Mar 5, 26 | BEDROSIAN CAMILLE L Officer |
STOCK | 95.99K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BEDROSIAN CAMILLE L |
Officer | 278.06K | Sale |
COHEN JOSHUA BARRY |
Chief Executive Officer | 3.61M | Sale |
FIRESTONE KAREN M. |
Director | 116.90K | Conversion of Exercise of derivative security |
FRATES JAMES MATTHEW |
Chief Financial Officer | 400.16K | Sale |
KLEE JUSTIN B |
Chief Executive Officer | 3.61M | Sale |
MAZZARIELLO GINA |
Officer | 190.84K | Sale |
MILNE GEORGE MCLEAN JR |
Director | 812.88K | Stock Gift |
ZEIHER BERNHARDT G |
Director | 10.00K | Purchase |
Fundamentals
Market cap$3.47B
Enterprise value$2.88B
Revenue (TTM)—
Gross profit$-92.45M
EBITDA$-161.73M
Net income$-152.09M
EPS (TTM)$-1.41
Free cash flow$-77.32M
Total cash$250.76M
Total debt$5.25M
Book value / share$2.15
Shares outstanding125.51M
Float97.25M
Short % of float13.48%
Dividend yield0.00%
Beta (5Y)-0.09
Valuation & profitability ratios
Trailing P/E—
Forward P/E-23.97
PEG ratio—
Price / sales—
Price / book12.89
EV / revenue—
EV / EBITDA-17.80
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-74.73%
Return on assets-44.13%
Debt / equity2.20
Current ratio12.12
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $87.37M | $380.79M | $22.23M | -100.0% |
| Operating revenue | $0 | $87.37M | $431.43M | $27.10M | -100.0% |
| Cost of revenue | $0 | $124.63M | $25.44M | $2.99M | -100.0% |
| Gross profit | $0 | -$37.26M | $355.35M | $19.24M | +100.0% |
| Research & development | $90.40M | $104.08M | $128.19M | $93.45M | -13.1% |
| Selling, general & admin | $62.89M | $114.33M | $188.36M | $127.13M | -45.0% |
| Total operating expense | $153.29M | $218.41M | $316.54M | $220.58M | -29.8% |
| Operating income | -$153.29M | -$255.68M | $38.80M | -$201.34M | +40.0% |
| Net interest income | $9.30M | $13.81M | $16.16M | $4.29M | -32.6% |
| Pre-tax income | -$144.69M | -$302.14M | $54.30M | -$197.60M | +52.1% |
| Tax provision | $46.00K | -$393.00K | $5.03M | $774.00K | +111.7% |
| Net income | -$144.74M | -$301.74M | $49.27M | -$198.38M | +52.0% |
| Net income to common | -$144.74M | -$301.74M | $49.27M | -$198.38M | +52.0% |
| Basic EPS | -1.53 | -4.43 | 0.73 | -3.39 | +65.5% |
| Diluted EPS | -1.53 | -4.43 | 0.70 | -3.39 | +65.5% |
| EBIT | -$153.29M | -$255.68M | $38.80M | -$201.34M | +40.0% |
| EBITDA | -$152.77M | -$254.77M | $39.89M | -$200.85M | +40.0% |
| Basic shares | 94.57M | 68.14M | 67.23M | 58.50M | +38.8% |
| Diluted shares | 94.57M | 68.14M | 69.99M | 58.50M | +38.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $226.65M | $77.39M | $170.20M | $62.53M | — | +192.9% |
| Cash & short-term investments | $316.98M | $176.50M | $371.36M | $346.94M | — | +79.6% |
| Accounts receivable | $88.00K | $447.00K | $40.05M | $15.31M | — | -80.3% |
| Inventory | — | $0 | $38.32M | $9.77M | $0 | — |
| Total current assets | $323.67M | $189.43M | $464.67M | $382.13M | — | +70.9% |
| Property, plant & equipment | $5.49M | $2.73M | $6.41M | $8.13M | — | +101.0% |
| Total assets | $332.64M | $193.63M | $517.45M | $391.45M | — | +71.8% |
| Total current liabilities | $22.69M | $28.41M | $82.04M | $46.61M | — | -20.1% |
| Total debt | $5.96M | $1.98M | $4.24M | $6.28M | — | +200.7% |
| Total liabilities | $27.39M | $28.87M | $84.02M | $50.85M | — | -5.1% |
| Retained earnings | -$751.43M | -$606.69M | -$304.95M | -$354.22M | — | -23.9% |
| Shareholder equity | $305.26M | $164.76M | $433.43M | $340.61M | — | +85.3% |
| Working capital | $300.98M | $161.03M | $382.62M | $335.52M | — | +86.9% |
| Net tangible assets | $305.26M | $164.76M | $433.43M | $340.61M | — | +85.3% |
| Shares issued | 109.88M | 68.63M | 67.71M | 66.51M | — | +60.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$144.74M | -$301.74M | $49.27M | -$198.38M | +52.0% |
| Depreciation & amortisation | $525.00K | $904.00K | $1.09M | $487.00K | -41.9% |
| Stock-based compensation | $27.64M | $33.04M | $37.16M | $21.71M | -16.3% |
| Change in working capital | -$1.08M | -$45.83M | -$65.66M | -$1.64M | +97.6% |
| Operating cash flow | -$123.34M | -$167.65M | $11.92M | -$179.87M | +26.4% |
| Capital expenditure | -$138.00K | -$157.00K | -$1.24M | -$2.53M | +12.1% |
| Investing cash flow | $14.04M | $75.65M | $92.05M | -$238.99M | -81.4% |
| Financing cash flow | $257.03M | $348.00K | $3.54M | $431.79M | +73,758.9% |
| Free cash flow | -$123.48M | -$167.80M | $10.68M | -$182.40M | +26.4% |
| End cash position | $227.64M | $78.84M | $170.92M | $63.24M | +188.7% |
One period below is a stub at the data source — the figures were never populated. Those cells read n/r rather than $0, because zero is not what was reported.
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 stub | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Cost of revenue | — | $0 | $0 | $0 | $0 | n/r | — |
| Gross profit | — | $0 | $0 | $0 | $0 | n/r | — |
| Research & development | $23.77M | $27.61M | $21.21M | $19.86M | $27.22M | — | -13.9% |
| Selling, general & admin | $21.93M | $16.17M | $15.39M | $16.17M | $15.64M | — | +35.6% |
| Total operating expense | $45.69M | $43.78M | $36.60M | $36.03M | $42.86M | — | +4.4% |
| Operating income | -$45.69M | -$43.78M | -$36.60M | -$36.03M | -$42.86M | — | -4.4% |
| Net interest income | $2.32M | $2.57M | $3.29M | $1.82M | $1.96M | — | -9.6% |
| Pre-tax income | -$43.42M | -$41.28M | -$32.95M | -$34.39M | -$41.44M | — | -5.2% |
| Tax provision | — | — | $46.00K | $0 | $0 | n/r | — |
| Net income | -$43.42M | -$41.28M | -$33.00M | -$34.39M | -$41.44M | — | -5.2% |
| Net income to common | -$43.42M | -$41.28M | -$33.00M | -$34.39M | -$41.44M | — | -5.2% |
| Basic EPS | -0.39 | -0.37 | -0.30 | -0.37 | -0.46 | — | -5.4% |
| Diluted EPS | -0.39 | -0.37 | -0.30 | -0.37 | -0.46 | — | -5.4% |
| EBIT | -$45.69M | -$43.78M | -$36.60M | -$36.03M | -$42.86M | — | -4.4% |
| EBITDA | -$45.65M | -$43.68M | -$36.50M | -$35.91M | -$42.72M | — | -4.5% |
| Basic shares | 111.20M | 110.56M | 109.84M | 93.33M | 89.14M | — | +0.6% |
| Diluted shares | 111.20M | 110.56M | 109.84M | 93.33M | 89.14M | — | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $49.33M | $229.14M | $226.65M | $225.18M | $58.09M | — | -78.5% |
| Cash & short-term investments | $250.76M | $279.77M | $316.98M | $343.99M | $180.83M | — | -10.4% |
| Accounts receivable | — | — | $88.00K | $132.00K | $103.00K | $300.00K | — |
| Total current assets | $256.34M | $285.02M | $323.67M | $353.38M | $186.89M | — | -10.1% |
| Property, plant & equipment | $4.74M | $5.09M | $5.49M | $5.88M | $6.26M | — | -6.9% |
| Total assets | $264.56M | $293.60M | $332.64M | $362.74M | $194.60M | — | -9.9% |
| Total current liabilities | $21.15M | $15.97M | $22.69M | $25.79M | $21.42M | — | +32.5% |
| Total debt | $5.25M | $5.63M | $5.96M | $5.93M | $5.96M | — | -6.7% |
| Total liabilities | $25.40M | $20.44M | $27.39M | $30.75M | $26.72M | — | +24.2% |
| Retained earnings | -$836.13M | -$792.71M | -$751.43M | -$718.43M | -$684.04M | — | -5.5% |
| Shareholder equity | $239.17M | $273.16M | $305.26M | $332.00M | $167.88M | — | -12.4% |
| Working capital | $235.19M | $269.06M | $300.98M | $327.59M | $165.47M | — | -12.6% |
| Net tangible assets | $239.17M | $273.16M | $305.26M | $332.00M | $167.88M | — | -12.4% |
| Shares issued | 111.37M | 111.03M | 109.88M | 109.77M | 89.16M | — | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$43.42M | -$41.28M | -$33.00M | -$34.39M | -$41.44M | — | -5.2% |
| Depreciation & amortisation | $43.00K | $98.00K | $108.00K | $120.00K | $141.00K | — | -56.1% |
| Stock-based compensation | $8.32M | $6.12M | $6.39M | $7.08M | $7.35M | — | +35.9% |
| Change in working capital | $4.82M | -$5.26M | $92.00K | -$1.94M | $9.96M | — | +191.7% |
| Operating cash flow | -$31.42M | -$36.88M | -$27.90M | -$30.37M | -$25.25M | — | +14.8% |
| Capital expenditure | — | — | -$86.00K | -$24.00K | -$17.00K | -$11.00K | — |
| Investing cash flow | -$149.80M | $36.26M | $29.47M | $5.24M | $22.99M | — | -513.1% |
| Financing cash flow | $1.48M | $3.22M | -$208.00K | $191.61M | -$31.00K | — | -54.0% |
| Free cash flow | -$31.45M | -$36.88M | -$27.99M | -$30.39M | -$25.27M | — | +14.7% |
| End cash position | $50.31M | $230.12M | $227.64M | $226.16M | $59.54M | — | -78.1% |
Options analytics
Put / call volume
2.68
Put-heavy session
Put / call open interest
0.91
Positioning, not flow
Max pain
35.00
+26.4% from spot
ATM implied vol
51.0%
Nearest strike to spot
Skew (10% OTM)
+16.0%
Puts bid over calls
Call volume
658
Contracts, this expiry
Put volume
1.76K
Contracts, this expiry
Heaviest call OI
45.00
1.17K contracts
Heaviest put OI
35.00
1.84K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.36 | -0.39 | -9.0% |
| Mar 2026 | -0.34 | -0.37 | -8.7% |
| Dec 2025 | -0.34 | -0.30 | +12.2% |
| Sep 2025 | -0.43 | -0.37 | +13.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.37 | 8 | $37.82K | 0.0% |
| Next quarter | -0.37 | 8 | -$37.82K | 0.0% |
| Current year | -1.50 | 8 | $0 | 0.0% |
| Next year | -1.15 | 8 | $28.23M | 0.0% |
Analyst targets & ownership
Mean target$42.36
High target$57.00
Low target$20.00
Implied upside53.05%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy0 / 11
Hold1
Sell / Strong sell0 / 0
Held by insiders7.18%
Held by institutions92.41%
Institutions holding282
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
28.72
-3.63% from price
SMA 20
30.64
-9.65% from price
SMA 50
29.85
-7.28% from price
SMA 100
22.92
+20.79% from price
SMA 200
18.75
+47.60% from price
EMA 12
29.16
-5.07% from price
EMA 26
30.03
-7.84% from price
EMA 50
28.67
-3.46% from price
RSI (14)
37.2
Neutral
MACD (12,26,9)
-0.88
Hist -0.58
ATR (14)
1.36
4.90% of price
Realised vol 30D
43.4%
Annualised
Bollinger upper
34.87
20, 2σ
Bollinger lower
26.40
20, 2σ
50 / 200 cross
Golden
29.85 vs 18.75
Trend bias
Above 200
+47.60%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.83
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
43.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-30.6%
Peak to trough
Max drawdown 5Y
-96.0%
Peak to trough
ATR 14
1.36
4.90% of price
Beta (reported)
-0.09
5Y monthly, from filing
Short interest
Shares short
13.51M
Prior 13.43M
Change vs prior
+0.7%
Shorts adding
% of float
13.48%
Elevated
% of shares out
10.77%
Against total outstanding
Days to cover
3.7
Liquid
Float
97.25M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 19, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Aug 19, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 19, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Aug 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 17, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Aug 3, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 20, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Jun 25, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Apr 28, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Mar 25, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 19, 26 | Guggenheim | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-08
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-04
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-23
Corporate Changes & Voting Matters
8-K · 2026-03-24
Corporate Changes & Voting Matters
8-K · 2026-03-03
Corporate Changes & Voting Matters
8-K · 2026-01-08
Headlines
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Business Wire · 1d ago
3 High Growth Stocks To Own In October 2026
Simply Wall St. · 3d ago
Amylyx Pharmaceuticals And 2 More Quality Growth Stocks
Simply Wall St. · 3d ago
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
MarketBeat · 4d ago
Our Pick Of The Best Growth Stocks In September 2026
Simply Wall St. · 12d ago
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Business Wire · 14d ago
Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
Business Wire · 28d ago
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
Business Wire · 29d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.